Last 12 months
Inside the activity.
0 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2015 Filed Mar 7, 2015 02:02 UTC |
Harper Sean EEVP, Research & Development
|
GrantCommon Stock | 54,577 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-010544 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,162 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,040 RSUs which vest in one installment of 2,040 on 4/25/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 3,940 RSUs which vest in two equal installments of 1,300 on 1/30/2017 and 1/30/2018 and one installment of 1,340 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 573 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 04, 2015 Filed Mar 7, 2015 02:03 UTC |
HOOPER ANTHONY CEVP, Global Commercial Ops.
|
GrantCommon Stock | 107,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-010545 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,688 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 4,597 RSUs which vest in two equal installments of 1,517 on 1/30/2017 and 1/30/2018 and one installment of 1,563 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 573 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 04, 2015 Filed Mar 7, 2015 02:06 UTC | GrantCommon Stock | 28,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-010546 · form4.xml · nonDerivative · entry 1 MCNAMEE BRIAN M · CIK 0001183885 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,214 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,550 RSUs which vest in one installment of 2,550 on 4/25/2015; 2,993 RSUs which vest in two annual installments of 1,474 and 1,519 on 4/27/2015 and 4/27/2016, respectively; 2,975 RSUs which vest in two installments of 1,465 and 1,510 on 1/28/2016 and 1/28/2017, respectively; 7,488 RSUs which vest in one installment of 3,688 on 10/25/2015 and one installment of 3,800 on 10/25/2016; 4,707 RSUs which vest in two equal installments of 1,553 on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018; and 3,677 RSUs which vest in two equal installments of 1,213 on 1/30/2017 and 1/30/2018 and one installment of 1,251 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 519 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
|
| March 04, 2015 Filed Mar 7, 2015 02:08 UTC |
Patton Cynthia MSVP & CCO
|
GrantCommon Stock | 7,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-010547 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,006 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 508 RSUs which vest in on 4/25/2015; 804 RSUs which vest in two annual installments of 396 on 4/27/2015 and 408 on 4/27/2016; 3,632 RSUs which vest in two installments of 1,789 and 1,843 on 10/26/2015 and 10/26/2016, respectively; 1,410 RSUs which vest in two installments of 694 and 716 on 1/28/2016 and 1/28/2017, respectively; 1,092 RSUs which vest in two equal installments of 360 on 1/31/2016 and 1/31/2017 and one installment of 372 on 1/31/2018; and 919 shares that vest in two equal installments of 303 on 1/30/2017 and 1/30/2018 and one installment of 313 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 263 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 04, 2015 Filed Mar 7, 2015 02:10 UTC |
Piacquad DavidSVP, Business Development
|
GrantCommon Stock | 9,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-010548 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,321 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 632 RSUs which fully vest on 4/25/2015; 1,005 RSUs which vest in two annual installments of 495 on 4/27/2015 and 510 on 4/27/2016; 840 RSUs which vest in two equal installments of 277 each on 4/26/2015 and 4/26/2016 and one installment of 286 on 4/26/2017; 9,226 RSUs which vest in two equal installments of 4,613 each on 4/26/2015 and 4/26/2017; 1,166 RSUs which vest in annual installments of 384, 385 and 397 on 4/25/2016, 4/25/2017 and 4/25/2018, respectively; and 1,050 RSUs which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 386 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| March 04, 2015 Filed Mar 7, 2015 02:12 UTC |
SCOTT DAVID JSVP, Gen. Counsel & Secy.
|
GrantCommon Stock | 38,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-010549 · form4.xml · nonDerivative · entry 1 SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,962 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,808 RSUs which vest in one installment on 4/25/2015; 4,115 RSUs which vest in two annual installments of 2,027 and 2,088 on 4/27/2015 and 4/27/2016, respectively; 3,601 RSUs which vest in one installment of 1,773 on 1/28/2016 and one installment of 1,828 on 1/28/2017; 3,362 RSUs which vest in two equal installments of 1,109 on 1/31/2016 and 1/31/2017 and one installment of 1,144 on 1/31/2018; and 2,627 RSUS which vest in three annual installments of 866, 867 and 894 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 406 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 04, 2015 Filed Mar 7, 2015 02:14 UTC |
Tross Stuart ASVP, Human Resources
|
GrantCommon Stock | 8,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-010550 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,561 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 179 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 03, 2015 Filed Mar 5, 2015 01:25 UTC |
Tross Stuart ASVP, Human Resources
|
SaleCommon Stock | 4,415 | $157.74 | $696,426.52 |
DisclosureSEC source: 0001127602-15-010218 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,237 F1 · price: The price reported is an average price. The prices ranged from $157.76 to $157.74 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 179 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 02, 2015 Filed Mar 4, 2015 01:52 UTC |
HOOPER ANTHONY CEVP, Global Commercial Ops.
|
Tax withholdingCommon Stock | 3,215 | $157.72 | $507,069.80 |
DisclosureSEC source: 0001127602-15-009819 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,334 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 4,597 RSUs which vest in two equal installments of 1,517 on 1/30/2017 and 1/30/2018 and one installment of 1,563 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 573 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 02, 2015 Filed Mar 4, 2015 01:55 UTC |
BALTIMORE DAVIDDirector
|
SaleCommon Stock | 3,647 | $158.76 | $579,011.21 |
DisclosureSEC source: 0001127602-15-009820 · form4.xml · nonDerivative · entry 1 BALTIMORE DAVID · CIK 0001185858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,159 F1 · price: The price reported is an average price. The prices ranged from $158.74 to $158.791 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 21:13 UTC |
BALTIMORE DAVIDDirector
|
Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $42.13 | $0.00 |
DisclosureSEC source: 0001127602-15-007689 · form4.xml · derivative · entry 3 BALTIMORE DAVID · CIK 0001185858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2015-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 21:13 UTC |
BALTIMORE DAVIDDirector
|
Tax withholdingCommon Stock | 1,353 | $155.78 | $210,770.34 |
DisclosureSEC source: 0001127602-15-007689 · form4.xml · nonDerivative · entry 2 BALTIMORE DAVID · CIK 0001185858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,806 F1 · balance_after: Non-market exercise of 5,000 stock options expiring April 29, 2015 wherein 1,353 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price, with the remaining shares delivered to the reporting person. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 21:13 UTC |
BALTIMORE DAVIDDirector
|
Exercise / conversionCommon Stock | 5,000 | $42.13 | $210,650.00 |
DisclosureSEC source: 0001127602-15-007689 · form4.xml · nonDerivative · entry 1 BALTIMORE DAVID · CIK 0001185858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2015 Filed Feb 13, 2015 02:09 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Exercise / conversionNqso (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $42.13 | $0.00 |
DisclosureSEC source: 0001127602-15-005887 · form4.xml · derivative · entry 6 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,000 shares Expires 2015-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2015 Filed Feb 13, 2015 02:09 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Exercise / conversionNqso (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $42.13 | $0.00 |
DisclosureSEC source: 0001127602-15-005887 · form4.xml · derivative · entry 5 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 62,000 shares Expires 2015-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2015 Filed Feb 13, 2015 02:09 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
SaleCommon Stock | 22,000 | $152.69 | $3,359,116.20 |
DisclosureSEC source: 0001127602-15-005887 · form4.xml · nonDerivative · entry 4 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,102 F2 · price: The price reported is an average price. The prices ranged from $152.68 to $152.78 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F3 · balance_after: Open market exercise of 22,000 stock options expiring April 29, 2015 wherein a portion of the cash received as a result of the exercise of these options was used to cover the option exercise price and the remaining balance was remitted in full by the Company to the appropriate California and federal taxing authorities. F4 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 7,140 RSUs which vest in one installment on 4/25/2015; 14,029 RSUs which vest in two installments of 6,910 and 7,119 on 4/27/2015 and 4/27/2016, respectively; 12,525 RSUs which vest in two installments of 6,169 and 6,356 on 1/28/2016 and 1/28/2017, respectively; 15,132 RSUs which vest in three installments of 4,993, 4,994 and 5,145 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 13,398 shares which vest in two equal installments of 4,421 on 1/30/2017 and 1/30/2018 and one installment of 4,556 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F5 · balance_after: These shares include 1,458 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 11, 2015 Filed Feb 13, 2015 02:09 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Exercise / conversionCommon Stock | 22,000 | $42.13 | $926,860.00 |
DisclosureSEC source: 0001127602-15-005887 · form4.xml · nonDerivative · entry 3 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2015 Filed Feb 13, 2015 02:09 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 40,539 | $152.57 | $6,185,035.23 |
DisclosureSEC source: 0001127602-15-005887 · form4.xml · nonDerivative · entry 2 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,102 F1 · balance_after: Non-market exercise of 62,000 stock options expiring April 29, 2015 wherein 40,539 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and statutory tax withholding, with the remaining shares delivered to the reporting person. Read SEC document |
| February 11, 2015 Filed Feb 13, 2015 02:09 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Exercise / conversionCommon Stock | 62,000 | $42.13 | $2,612,060.00 |
DisclosureSEC source: 0001127602-15-005887 · form4.xml · nonDerivative · entry 1 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2015 Filed Feb 6, 2015 23:23 UTC |
COFFMAN VANCE DDirector
|
Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $42.13 | $0.00 |
DisclosureSEC source: 0001127602-15-004908 · form4.xml · derivative · entry 3 COFFMAN VANCE D · CIK 0001193998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2015-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2015 Filed Feb 6, 2015 23:23 UTC |
COFFMAN VANCE DDirector
|
Tax withholdingCommon Stock | 1,374 | $153.36 | $210,716.64 |
DisclosureSEC source: 0001127602-15-004908 · form4.xml · nonDerivative · entry 2 COFFMAN VANCE D · CIK 0001193998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,086 F1 · balance_after: Non-market exercise of 5,000 stock options expiring April 29, 2015 wherein 1,374 shares issuable pursuant to the exercise of these otions were withheld by the Company to cover the option exercise price, with the remaiing shares delivered to the reporting person. These shares include 466 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 06, 2015 Filed Feb 6, 2015 23:23 UTC |
COFFMAN VANCE DDirector
|
Exercise / conversionCommon Stock | 5,000 | $42.13 | $210,650.00 |
DisclosureSEC source: 0001127602-15-004908 · form4.xml · nonDerivative · entry 1 COFFMAN VANCE D · CIK 0001193998 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2015 Filed Feb 6, 2015 01:11 UTC |
HERRINGER FRANK CDirector
|
Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $42.13 | $0.00 |
DisclosureSEC source: 0001127602-15-004658 · form4.xml · derivative · entry 7 HERRINGER FRANK C · CIK 0001171694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2015-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2015 Filed Feb 6, 2015 01:11 UTC |
HERRINGER FRANK CDirector
|
PurchaseCommon Stock | 1,500 | $152.29 | $228,435.00 |
DisclosureSEC source: 0001127602-15-004658 · form4.xml · nonDerivative · entry 4 HERRINGER FRANK C · CIK 0001171694 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Sarah Herringer 2012 Trust Disclosed balance after: 2,000 Read SEC document |
| February 05, 2015 Filed Feb 6, 2015 01:11 UTC |
HERRINGER FRANK CDirector
|
PurchaseCommon Stock | 1,500 | $152.29 | $228,435.00 |
DisclosureSEC source: 0001127602-15-004658 · form4.xml · nonDerivative · entry 3 HERRINGER FRANK C · CIK 0001171694 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Julia Herringer 2012 Trust Disclosed balance after: 2,000 Read SEC document |
| February 05, 2015 Filed Feb 6, 2015 01:11 UTC |
HERRINGER FRANK CDirector
|
Tax withholdingCommon Stock | 1,391 | $151.45 | $210,666.95 |
DisclosureSEC source: 0001127602-15-004658 · form4.xml · nonDerivative · entry 2 HERRINGER FRANK C · CIK 0001171694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,058 F1 · balance_after: Non-market net exercise of 5,000 stock options expiring April 29, 2015 wherein 1,391 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price, with the remaining shares delivered to the reporting person. These shares include 881 Dividend Equivalent (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 05, 2015 Filed Feb 6, 2015 01:11 UTC |
HERRINGER FRANK CDirector
|
Exercise / conversionCommon Stock | 5,000 | $42.13 | $210,650.00 |
DisclosureSEC source: 0001127602-15-004658 · form4.xml · nonDerivative · entry 1 HERRINGER FRANK C · CIK 0001171694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2015 Filed Feb 3, 2015 23:55 UTC |
Balachandran MadhavanEVP, Operations
|
GrantCommon Stock | 3,677 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004126 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,507 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,530 RSUs which vest in one installment on 4/25/2015; 1,684 RSUs which vest in two installments of 829 and 855 on 4/27/2015 and 4/27/2016, respectively; 17,845 RSUs which vest in one installment of 8,789 on 7/31/2015 and one installment of 9,056 on 7/31/2016; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 4,707 RSUs which vest in two equal installments of 1,553 each on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018; and 3,677 RSUs which vest in two equal installments of 1,213 on 1/30/2017 and 1/30/2018 and one installment of 1,251 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,054 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2015 Filed Feb 3, 2015 23:58 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
GrantCommon Stock | 13,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004130 · form4.xml · nonDerivative · entry 1 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,641 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended ad Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 7,140 RSUs which vest in one installment on 4/25/2015; 14,029 RSUs which vest in two installments of 6,910 and 7,119 on 4/27/2015 and 4/27/2016, respectively; 12,525 RSUs which vest in two installments of 6,169 and 6,356 on 1/28/2016 and 1/28/2017, respectively; 15,132 RSUs which vest in three installments of 4,993, 4,994 and 5,145 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 13,398 shares which vest in two equal installments of 4,421 on 1/30/2017 and 1/30/2018 and one installment of 4,556 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,458 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2015 Filed Feb 4, 2015 00:01 UTC |
Harper Sean EEVP, Research & Development
|
GrantCommon Stock | 3,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004132 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,585 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 2,040 RSUs which vest in one installment of 2,040 on 4/25/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 5,101 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 3,940 RSUs which vest in two equal installments of 1,300 on 1/30/2017 and 1/30/2018 and one installment of 1,340 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 573 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2015 Filed Feb 4, 2015 00:02 UTC |
HOOPER ANTHONY CEVP, Global Commercial Ops.
|
GrantCommon Stock | 4,597 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004133 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,549 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 7,239 RSUs which vest in one installment on 3/2/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 5,101 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 4,597 RSUs which vest in two equal installments of 1,517 on 1/30/2017 and 1/30/2018 and one installment of 1,563 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 573 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2015 Filed Feb 4, 2015 00:05 UTC | GrantCommon Stock | 3,677 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004138 · form4.xml · nonDerivative · entry 1 MCNAMEE BRIAN M · CIK 0001183885 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,045 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 2,550 RSUs which vest in one installment of 2,550 on 4/25/2015; 2,993 RSUs which vest in two annual installments of 1,474 and 1,519 on 4/27/2015 and 4/27/2016, respectively; 2,975 RSUs which vest in two installments of 1,465 and 1,510 on 1/28/2016 and 1/28/2017, respectively; 7,488 RSUs which vest in one installment of 3,688 on 10/25/2015 and one installment of 3,800 on 10/25/2016; 4,707 RSUs which vest in two equal installments of 1,553 on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018; and 3,677 RSUs which vest in two equal installments of 1,213 on 1/30/2017 and 1/30/2018 and one installment of 1,251 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 519 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
|
| January 30, 2015 Filed Feb 4, 2015 00:07 UTC |
Meline David WEVP & CFO
|
GrantCommon Stock | 3,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004139 · form4.xml · nonDerivative · entry 1 Meline David W · CIK 0001444612 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,537 F1 · shares: These Restricted Stock Units (RSUs) were granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 54,161 RSUs which vest in three equal installments of 13,540 on 8/1/2015, 8/1/2016 and 8/1/2017 and one installment of 13,541 on 8/1/2018; and 3,940 RSUs whicdh vest in two equal installments of 1,300 on 1/30/2017 and 1/30/2018 and one installment of 1/340 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 436 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2015 Filed Feb 4, 2015 00:09 UTC |
Patton Cynthia MSVP & CCO
|
GrantCommon Stock | 919 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004141 · form4.xml · nonDerivative · entry 1 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,439 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 508 RSUs which vest in on 4/25/2015; 804 RSUs which vest in two annual installments of 396 on 4/27/2015 and 408 on 4/27/2016; 3,632 RSUs which vest in two installments of 1,789 and 1,843 on 10/26/2015 and 10/26/2016, respectively; 1,410 RSUs which vest in two installments of 694 and 716 on 1/28/2016 and 1/28/2017, respectively; 1,092 RSUs which vest in two equal installments of 360 on 1/31/2016 and 1/31/2017 and one installment of 372 on 1/31/2018; and 919 RSUs which vest in two equal installments of 303 on 1/30/2017 and 1/30/2018 and one installment of 313 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 263 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2015 Filed Feb 4, 2015 00:12 UTC |
Piacquad DavidSVP, Business Development
|
GrantCommon Stock | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004145 · form4.xml · nonDerivative · entry 1 Piacquad David · CIK 0001602343 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,862 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 632 RSUs which fully vest on 4/25/2015; 1,005 RSUs which vest in two annual installments of 495 on 4/27/2015 and 510 on 4/27/2016; 840 RSUs which vest in two equal installments of 277 each on 4/26/2015 and 4/26/2016 and one installment of 286 on 4/26/2017; 9,226 RSUs which vest in two equal installments of 4,613 each on 4/26/2015 and 4/26/2017; 1,166 RSUs which vest in annual installments of 384, 385 and 397 on 4/25/2016, 4/25/2017 and 4/25/2018, respectively; and 1,050 RSUs which vest in three annual installments of 346, 347 and 357 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 386 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. Read SEC document |
| January 30, 2015 Filed Feb 4, 2015 00:14 UTC |
SCOTT DAVID JSVP, Gen. Counsel & Secy.
|
GrantCommon Stock | 2,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004146 · form4.xml · nonDerivative · entry 1 SCOTT DAVID J · CIK 0001145154 · SVP, Gen. Counsel & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,230 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 3,808 RSUs which vest in one installment on 4/25/2015; 4,115 RSUs which vest in two annual installments of 2,027 and 2,088 on 4/27/2015 and 4/27/2016, respectively; 3,601 RSUs which vest in one installment of 1,773 on 1/28/2016 and one installment of 1,828 on 1/28/2017; 3,362 RSUs which vest in two equal installments of 1,109 on 1/31/2016 and 1/31/2017 and one installment of 1,144 on 1/31/2018; and 2,627 RSUS which vest in three annual installments of 866, 867 and 894 on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 406 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2015 Filed Feb 4, 2015 00:16 UTC |
Tross Stuart ASVP, Human Resources
|
GrantCommon Stock | 1,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004148 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,652 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 179 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:50 UTC |
Balachandran MadhavanEVP, Operations
|
GiftCommon Stock | 1,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-003483 · form4.xml · nonDerivative · entry 4 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,830 F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,530 RSUs which vest in one installment on 4/25/2015; 1,684 RSUs which vest in two installments of 829 and 855 on 4/27/2015 and 4/27/2016, respectively; 17,845 RSUs which vest in one installment of 8,789 on 7/31/2015 and one installment of 9,056 on 7/31/2016; 5,010 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; and 4,707 RSUs which vest in two equal installments of 1,553 each on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,054 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:50 UTC |
Balachandran MadhavanEVP, Operations
|
GiftCommon Stock | 1,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-003483 · form4.xml · nonDerivative · entry 3 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 47,755 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:50 UTC |
Balachandran MadhavanEVP, Operations
|
Tax withholdingCommon Stock | 33 | $158.89 | $5,243.37 |
DisclosureSEC source: 0001127602-15-003483 · form4.xml · nonDerivative · entry 2 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,484 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:50 UTC |
Balachandran MadhavanEVP, Operations
|
Tax withholdingCommon Stock | 871 | $158.89 | $138,393.19 |
DisclosureSEC source: 0001127602-15-003483 · form4.xml · nonDerivative · entry 1 Balachandran Madhavan · CIK 0001555508 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,517 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:53 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 101 | $158.89 | $16,047.89 |
DisclosureSEC source: 0001127602-15-003485 · form4.xml · nonDerivative · entry 2 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,243 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 7,140 RSUs which vest in one installment on 4/25/2015; 14,029 RSUs which vest in two installments of 6,910 and 7,119 on 4/27/2015 and 4/27/2016, respectively; 12,525 RSUs which vest in two installments of 6,169 and 6,356 on 1/28/2016 and 1/28/2017, respectively; and 15,132 RSUs which vest in three installments of 4,993, 4,994 and 5,145 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 1,458 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:53 UTC |
Bradway Robert ADirector · Chairman, CEO and President
|
Tax withholdingCommon Stock | 2,317 | $158.89 | $368,148.13 |
DisclosureSEC source: 0001127602-15-003485 · form4.xml · nonDerivative · entry 1 Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,344 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:56 UTC |
Harper Sean EEVP, Research & Development
|
Tax withholdingCommon Stock | 35 | $158.89 | $5,561.15 |
DisclosureSEC source: 0001127602-15-003486 · form4.xml · nonDerivative · entry 2 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,645 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,040 RSUs which vest in one installment of 2,040 on 4/25/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 5,101 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 573 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:56 UTC |
Harper Sean EEVP, Research & Development
|
Tax withholdingCommon Stock | 928 | $158.89 | $147,449.92 |
DisclosureSEC source: 0001127602-15-003486 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,680 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:58 UTC |
HOOPER ANTHONY CEVP, Global Commercial Ops.
|
Tax withholdingCommon Stock | 35 | $158.89 | $5,561.15 |
DisclosureSEC source: 0001127602-15-003487 · form4.xml · nonDerivative · entry 2 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,952 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 7,239 RSUs which vest in one installment on 3/2/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 5,101 RSUs which vest in one installment of 2,467 on 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 573 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 21:58 UTC |
HOOPER ANTHONY CEVP, Global Commercial Ops.
|
Tax withholdingCommon Stock | 924 | $158.89 | $146,814.36 |
DisclosureSEC source: 0001127602-15-003487 · form4.xml · nonDerivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · EVP, Global Commercial Ops. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,987 Read SEC document |
| January 28, 2015 Filed Jan 30, 2015 22:03 UTC | Tax withholdingCommon Stock | 20 | $158.89 | $3,177.80 |
DisclosureSEC source: 0001127602-15-003490 · form4.xml · nonDerivative · entry 2 MCNAMEE BRIAN M · CIK 0001183885 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,368 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,550 RSUs which vest in one installment of 2,550 on 4/25/2015; 2,993 RSUs which vest in two annual installments of 1,474 and 1,519 on 4/27/2015 and 4/27/2016, respectively; 2,975 RSUs which vest in two installments of 1,465 and 1,510 on 1/28/2016 and 1/28/2017, respectively; 7,488 RSUs which vest in one installment of 3,688 on 10/25/2015 and one installment of 3,800 on 10/25/2016; and 4,707 RSUs which vest in two equal installments of 1,553 on 1/31/2016 and 1/31/2017 and one installment of 1,601 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 519 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
|
| January 28, 2015 Filed Jan 30, 2015 22:03 UTC | Tax withholdingCommon Stock | 518 | $158.89 | $82,305.02 |
DisclosureSEC source: 0001127602-15-003490 · form4.xml · nonDerivative · entry 1 MCNAMEE BRIAN M · CIK 0001183885 · EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,388 Read SEC document |
|
| January 28, 2015 Filed Jan 30, 2015 22:05 UTC |
Patton Cynthia MSVP & CCO
|
Tax withholdingCommon Stock | 10 | $158.89 | $1,588.90 |
DisclosureSEC source: 0001127602-15-003494 · form4.xml · nonDerivative · entry 2 Patton Cynthia M · CIK 0001560565 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,520 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 508 RSUs which vest in on 4/25/2015; 804 RSUs which vest in two annual installments of 396 on 4/27/2015 and 408 on 4/27/2016; 3,632 RSUs which vest in two installments of 1,789 and 1,843 on 10/26/2015 and 10/26/2016, respectively; 1,410 RSUs which vest in two installments of 694 and 716 on 1/28/2016 and 1/28/2017, respectively; and 1,092 RSUs which vest in two equal installments of 360 on 1/31/2016 and 1/31/2017 and one installment of 372 on 1/31/2018. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 263 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.